relaxin family peptide receptor 2Genealiases: GPR106 · GREAT · INSL3R · LGR8 · LGR8.1 · RXFPR2
Q-omics provides the consensus-scored RXFP2 profile across patient tissues and cancer cell-line models. RXFP2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RXFP2 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, RXFP2 RNA expression shows 7,238 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, and LSCC as cancer lineages where RXFP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RXFP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RXFP2 survival associations across molecular data types. RXFP2 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RXFP2 RNA expression–survival associations across cancer types. High RXFP2 expression shows unfavorable associations in READ and STAD, but favorable associations in LUAD, LGG, CESC and ESCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify LUAD as the clearest survival context for RXFP2 RNA expression.
This table summarizes RXFP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RXFP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RXFP2 shows lower tumor expression in LUAD, LUSC, READ, UCEC and KIRP. The LUAD box plot shows higher RXFP2 RNA expression in normal versus tumor tissue (log2 FC = −0.797, t-test p < 0.001).
This table shows molecular features associated with RXFP2 in patient tissues and cancer cell lines. In patient samples, RXFP2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RXFP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LUNG_NSCLC_LUAD.
